AT291440B - Verfahren zur Herstellung einer multivalente Vaccine - Google Patents

Verfahren zur Herstellung einer multivalente Vaccine

Info

Publication number
AT291440B
AT291440B AT855669A AT855669A AT291440B AT 291440 B AT291440 B AT 291440B AT 855669 A AT855669 A AT 855669A AT 855669 A AT855669 A AT 855669A AT 291440 B AT291440 B AT 291440B
Authority
AT
Austria
Prior art keywords
production
multivalent vaccine
multivalent
vaccine
Prior art date
Application number
AT855669A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of AT291440B publication Critical patent/AT291440B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT855669A 1968-09-11 1969-09-09 Verfahren zur Herstellung einer multivalente Vaccine AT291440B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75923768A 1968-09-11 1968-09-11

Publications (1)

Publication Number Publication Date
AT291440B true AT291440B (de) 1971-07-12

Family

ID=25054907

Family Applications (1)

Application Number Title Priority Date Filing Date
AT855669A AT291440B (de) 1968-09-11 1969-09-09 Verfahren zur Herstellung einer multivalente Vaccine

Country Status (10)

Country Link
AT (1) AT291440B (de)
BE (1) BE738674A (de)
BR (1) BR6912333D0 (de)
DE (1) DE1944956A1 (de)
ES (1) ES371256A1 (de)
FR (1) FR2017790A1 (de)
IE (1) IE33311B1 (de)
IL (1) IL32922A (de)
NL (1) NL6913032A (de)
ZA (1) ZA695453B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2633518B1 (fr) * 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues

Also Published As

Publication number Publication date
ES371256A1 (es) 1972-04-01
BE738674A (de) 1970-03-10
NL6913032A (de) 1970-03-13
DE1944956A1 (de) 1970-03-19
IL32922A0 (en) 1969-11-30
IE33311L (en) 1970-03-11
ZA695453B (en) 1971-03-31
FR2017790A1 (en) 1970-05-22
BR6912333D0 (pt) 1973-04-12
IL32922A (en) 1973-01-30
IE33311B1 (en) 1974-05-15

Similar Documents

Publication Publication Date Title
CH515117A (de) Verfahren zur Herstellung einer Holzspanplatte
CH517211A (de) Verfahren zur Herstellung eines Textilklebers
AT303261B (de) Verfahren zur Herstellung eines Zahnpflegemittels
AT306617B (de) Verfahren zur Herstellung eines feuerfesten Bauteiles
AT270874B (de) Verfahren zur Herstellung eines Zahnpflegemittels
AT319602B (de) Verfahren zur Herstellung einer Polyurethanmasse
AT281410B (de) Verfahren zur Herstellung wasserlöslicher Kunstharze
AT305491B (de) Verfahren zur Herstellung eines neuen Kombinationspräparates
CH517821A (de) Verfahren zur Herstellung einer Pigmentzubereitung
AT284605B (de) Verfahren zur Herstellung einer Gelierhilfe
CH525026A (de) Verfahren zur Herstellung eines Magnesium-Aluminium-Spinell-Einkristalls
CH502278A (de) Verfahren zur Herstellung einer Glaskeramik
AT308666B (de) Verfahren zur Herstellung eines Hefevorteiges
AT300192B (de) Verfahren zur Herstellung eines Penicillinpräparates
AT309298B (de) Verfahren zur Herstellung einer glasfaserbeschichteten Gipsbauplatte
AT282821B (de) Verfahren zur Herstellung einer antigenfreien Vaccine
AT265517B (de) Verfahren zur Herstellung einer Vaccine gegen Staupe
AT297218B (de) Verfahren zur Herstellung einer zellfreien Penicillinacylase
AT290610B (de) Verfahren zur Herstellung eines Betonausbaues
AT299048B (de) Verfahren zur Herstellung eines Leichtbetonkörpers
CH515993A (de) Verfahren zur Herstellung einer Dextrinlösung
AT286497B (de) Verfahren zur Herstellung einer Vaccine
AT295449B (de) Verfahren zur Herstellung einer neuen Carboxypeptidase
AT277460B (de) Verfahren zur Herstellung einer Tetanus-Vaccine
AT308967B (de) Verfahren zur Herstellung einer Lebendvaccine

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee